p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia Journal Article

Authors: Zhang, J; Seet, C. S.; Sun, C.; Li, J; You, D.; Volk, A; Breslin, P; Li, X; Wei, W.; Qian, Z.; Zeleznik-Le, N. J.; Zhang, Z
Article Title: p27kip1 maintains a subset of leukemia stem cells in the quiescent state in murine MLL-leukemia
Abstract: MLL (mixed-lineage leukemia)-fusion genes induce the development of leukemia through deregulation of normal MLL target genes, such as HOXA9 and MEIS1. Both HOXA9 and MEIS1 are required for MLL-fusion gene-induced leukemogenesis. Co-expression of HOXA9 and MEIS1 induces acute myeloid leukemia (AML) similar to that seen in mice in which MLL-fusion genes are over-expressed. p27(kip1) (p27 hereafter), a negative regulator of the cell cycle, has also been defined as an MLL target, the expression of which is up-regulated in MLL leukemic cells (LCs). To investigate whether p27 plays a role in the pathogenesis of MLL-leukemia, we examined the effects of p27 deletion (p27(-/-)) on MLL-AF9 (MA9)-induced murine AML development. HOXA9/MEIS1 (H/M)-induced, p27 wild-type (p27(+/+)) and p27(-/-) AML were studied in parallel as controls. We found that LCs from both MA9-AML and H/M-AML can be separated into three fractions, a CD117(-)CD11b(hi) differentiated fraction as well as CD117(+)CD11b(hi) and CD117(+)CD11b(lo), two less differentiated fractions. The CD117(+)CD11b(lo) fraction, comprising only 1-3% of total LCs, expresses higher levels of early hematopoietic progenitor markers but lower levels of mature myeloid cell markers compared to other populations of LCs. p27 is expressed and is required for maintaining the quiescent and drug-resistant states of the CD117(+)CD11b(lo) fraction of MA9-LCs but not of H/M-LCs. p27 deletion significantly compromises the leukemogenic capacity of CD117(+)CD11b(lo) MA9-LCs by reducing the frequency of leukemic stem cells (LSCs) but does not do so in H/M-LCs. In addition, we found that p27 is highly expressed and required for cell cycle arrest in the CD117(-)CD11b(hi) fraction in both types of LCs. Furthermore, we found that c-Myc expression is required for maintaining LCs in an undifferentiated state independently of proliferation. We concluded that p27 represses the proliferation of LCs, which is specifically required for maintaining the quiescent and drug-resistant states of a small subset of MA9-LSCs in collaboration with the differentiation blockage function of c-Myc.
Journal Title: Molecular oncology
Volume: 7
Issue: 6
ISSN: 1878-0261; 1574-7891
Publisher: Unknown  
Journal Place: Netherlands
Date Published: 2013
Start Page: 1069
End Page: 1082
Language: eng
Notes: LR: 20150520; CI: Published by Elsevier B.V.; GR: R01 CA140979/CA/NCI NIH HHS/United States; GR: R01 HL095896/HL/NHLBI NIH HHS/United States; GR: R01 HL95896/HL/NHLBI NIH HHS/United States; GR: T32 HL066992/HL/NHLBI NIH HHS/United States; JID: 101308230; 0 (Antigens, CD11b); 0 (Cdkn1b protein, mouse); 0 (Homeodomain Proteins); 0 (Myc protein, mouse); 0 (Neoplasm Proteins); 0 (Proto-Oncogene Proteins c-myc); 0 (Tumor Markers, Biological); 0 (homeobox protein HOXA9); 0 (myeloid ecotropic viral integration site 1 protein); 147604-94-2 (Cyclin-Dependent Kinase Inhibitor p27); EC (Proto-Oncogene Proteins c-kit); NIHMS517708; OID: NLM: NIHMS517708; OID: NLM: PMC3898829; OTO: NOTNLM; 2013/06/07 [received]; 2013/07/22 [revised]; 2013/07/31 [accepted]; 2013/08/20 [aheadofprint]; ppublish